Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, The Takeda Oncology Company, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 100,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals Inc. ... on the development and commercialization of products for the ... will release results for the first quarter of 2015 ... The Company will host a conference ... 2015, during which Vanda management will discuss the first ...
(Date:4/16/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... on Tuesday, April 21, 2015, after the close of ... by a conference call with the investment community at ... will be Robert A. Bradway , chairman and ... management team. Live audio of the conference ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... SCOTTSDALE, Ariz., Feb. 14, 2012  Cayenne Medical, Inc., a ... of a $10 million equity financing, with new investor ... MB Venture Partners and Investor Growth Capital. The proceeds ... distribution and to support expansion of its portfolio of ...
... 2012 Leading events organiser UBM Live , a ... of Jim Buckley as the new Brand Director for Informex. ... value chemistry via a comprehensive calendar of conferences and events, ... is run in partnership with the Society of Chemical Manufacturers ...
Cached Medicine Technology:Cayenne Medical Closes $10 Million Capital Raise 2UBM Live Appoints Jim Buckley as Informex Brand Director 2UBM Live Appoints Jim Buckley as Informex Brand Director 3
(Date:4/19/2015)... York (PRWEB) April 19, 2015 New ... Multidistrict Litigation (JPML) indicate that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... in U.S. District Court, District of South Carolina. According ... cases have been filed in the proceeding on behalf ... to their use of the cholesterol-lowering statin. This represents ...
(Date:4/19/2015)... Hanover, MA (PRWEB) April 19, 2015 Family ... Bowling for Brains in Memory of Brad Baddeley ... renowned Brain Aneurysm Foundation. , Bowling for Brains is cheduled ... Bowling located 4700 Dudley Street in Lincoln, Nebraska. Participants may ... from 1:00 to 3:00pm. , The cost is only $4 ...
(Date:4/18/2015)... Carinsurancequotesinfo.com has released a new blog post explaining ... caused by a car accident. , Car insurance ... A policy can pay for car repairs and even ... carry appropriate coverage when they are driving. ... several important riders that offer extra coverage options. One ...
(Date:4/18/2015)... Review of Ophthalmology magazine and Abbot Medical ... program for cataract surgeons attending the American Society of ... eye surgeon Jeffrey L. Martin, MD will serve as ... is the Managing Partner of North Shore Eye Care. ... to lead this year’s discussion on the latest breakthroughs ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... 10, 2007 The sleep patterns of patients in ... barely spend any time in the restorative stages of ... physicians have found. , Current clinical-care protocols routinely and ... time when the need for adequate rest is perhaps ...
... Overall Survival Advantage in Elderly Myeloma ... Added to Standard Therapy - Data Presented at ... Dec. 9 Pharmion Corporation (Nasdaq:,PHRM) today announced final ... that the addition of,Thalidomide to standard treatment improves survival ...
... - Two drugs approved for use as second line therapy ... therapy for newly diagnosed patients in two clinical trials, research ... D. Anderson Cancer Center report at the 49th annual meeting ... patients in both trials have a complete cytogenetic response - ...
... Health & Science University Cancer Institute researchers have opened a ... , We are looking under the surface of CML to ... have discovered abnormal cells in the early stem cell population ... clone. These are abnormal cells that are not part of ...
... off going to the doctor or overindulge in unhealthy ... -- The holiday season is also the season for ... of the Vanderbilt Heart and Vascular Institute at Vanderbilt ... Churchwell, a look at a U.S. database of 53 ...
... GA, December 8, 2007 -- Results from two investigational ... bortezomib provide preliminary anti-tumor activity in patients with relapsed ... showed that 10 of 21 (48 percent) evaluable patients ... and bortezomib combination treatment. Data from a second ...
Cached Medicine News:Health News:Physicians seek to improve the quality of sleep in ICU, researchers at UT Southwestern report 2Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 2Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 3Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 4Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 5Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 6Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 7Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia 2Health News:Heart Attacks Peak During the Holidays 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
... Whether you prefer silicone or ... Specialty Stents help promote healing after ... guards against anastomotic stricture, supports the ... the prevention of postoperative leakage. Following ...
... The Max-Blade™ Coagulating Resector is a device that ... This patented design was developed to provide the ... same high quality pathology chip, the approximate speed ... enjoyed with a standard loop but with ...
... Used for stone manipulation and removal in ... the basket to retain its shape following extreme ... stone capture by allowing the basket to open ... the stone. The tipless design reduces the likelihood ...
Medicine Products: